PrimeC can significantly slow ALS progression: PARADIGM trial
An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
Study record managers: refer to the Data Element Definitions if submitting registration or results information.| clinicaltrials.gov
Lindsey Shapiro is a science writer for ALS News Today with a PhD in neuroscience. She covers the latest news and information on a variety of amyotrophic lateral sclerosis topics.| ALS News Today
Category archive page for Columns.| ALS News Today
Starting treatment with PrimeC six months sooner was associated with slower disease progression and a survival benefit for ALS patients.| ALS News Today
ALS is a neurodegenerative disorder marked by progressively worsening muscle weakness and neurological dysfunction.| ALS News Today
Category archive page for News.| ALS News Today
ALS is a progressive neurological disorder that damages motor neurons. Learn more about types, causes, symptoms, diagnosis, and treatment.| ALS News Today
